Rhythm Pharmaceuticals
Rhythm Pharmaceuticals - Rhythm is developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders..
loading funding rounds…
NEA(exited)
Pfizer Ventures(exited)
Deerfield Capital Management(exited)
Ipsen(exited)
MPM BioImpact(exited)
OrbiMed(exited)
Third Rock Ventures(exited)
Wellington Management(exited)
Deerfield(exited)
Takeda(exited)
HealthCare Royalty(exited)
Allergan(exited)
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 649 % | 228 % | 68 % | 35 % | 75 % | 80 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (5392 %) | (744 %) | (218 %) | (190 %) | (95 %) | (29 %) | 1 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (2207 %) | (766 %) | (239 %) | (200 %) | (97 %) | (28 %) | 21 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 3301 % | 460 % | 174 % | 183 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Rhythm Pharmaceuticals
Edit
ACQUISITION by Rhythm Pharmaceuticals Feb 2023